Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Oppositional Defiant, Conduct Disorder
Interventions
Mobile Health Applictaion
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Conditions
ADHD
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
7 Years to 110 Years
Enrollment
3,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
2
States / cities
Orange, California • Bethesda, Maryland
Conditions
ADHD
Interventions
methylphenidate HCl, Mixed amphetamine salts extended release
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Brookline, Massachusetts
Conditions
Control Condition, Intervention Condition
Interventions
Collaborative Life Skills dHealth tool (CLS-D)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
7 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

NCT03680885
Conditions
ADHD, Controls
Interventions
Lidocaine gel, Placebo, Injected lidocaine
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
MDX, Placebo
Drug
Lead sponsor
Alcobra Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
36
States / cities
Dothan, Alabama • Los Alamitos, California • Newport Beach, California + 32 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
ADHD
Interventions
FRx-001, FRx-003, FRx-004
Device
Lead sponsor
Revibe Technologies
Industry
Eligibility
8 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Wake Forest, North Carolina
Active, not recruiting Not applicable Interventional

Efficacy of the Apollo System for Children With ADHD

NCT05308706
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
8 weeks of home based use.
Device
Lead sponsor
Michigan State University
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
East Lansing, Michigan
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Intermittent Theta-Burst Stimulation, Sham Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Obesity Treatment Enhanced With Working Memory Training

NCT02529397
Conditions
ADHD, Weight Loss
Interventions
Adaptive Working Memory Training, Non-adaptive cognitive training
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
Interventions
methylphenidate, guanfacine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Conditions
Childhood Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder, Parent-Child Interactions
Interventions
Triple P--Positive Parenting Program
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
3 Years to 7 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Columbia, South Carolina
Conditions
Posttraumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
RFPP, TFCBT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Accepts healthy volunteers

Prevention of School Dropout for Mexican American Adolescents

NCT00051727
Conditions
Depression, Conduct Disorder
Interventions
Bridges to High School Project
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
10 Years to 15 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Tempe, Arizona
Completed No phase listed Observational Accepts healthy volunteers

Studies of Brain and Body Interaction

NCT03672266
Conditions
Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease, Parkinson, Tremor Essential, Dementia, Alzheimer Type, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia With Lewy Bodies, Dementia Frontal
Interventions
Not listed
Lead sponsor
Rutgers University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Conditions
ADHD
Interventions
CLONICEL (clonidine HCl sustained release), Placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 18 more
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Withdrawn Not applicable Interventional Accepts healthy volunteers

Helping Toddlers and Parents Together

NCT04864808
Conditions
ADHD, Parenting
Interventions
Behavioral Parent Training
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
12 Months to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

NCT01415440
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Motivated Behavior in Adults With and Without ADHD

NCT02630017
Conditions
ADHD
Interventions
ADHD methylphenidate first, placebo second, ADHD placebo first, methylphenidate second, Non-ADHD methylphenidate first, placebo second, Non-ADHD placebo first, methylphenidate second
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas